Sarepta Therapeutics Announces That U.S. FDA has Accepted Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy
2022-11-28
Dear Investor,
Please find attached a press release by Sarepta Therapeutics regarding the FDA acceptance of filing and priority review of our partnered DMD asset:
Do not hesitate to contact us for any further questions.
With best regards,
| Roche Investor Relations | |
| Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com | Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
| Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com | Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com |
| Investor Relations North America | |
| Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
Investors
Investor updates
stay updated
get the latest news and updates to your inbox.